Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Paraganglioma × vandetanib × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Carcinoma, Medullary 5 Thyroid Neoplasms 4 Thyroid Cancer, Papillary 2 Familial medullary thyroid carcinoma 2 Adenocarcinoma, Follicular 2 Thyroid cancer, medullary 1 Thyroid Diseases 1 Thyroid Carcinoma, Anaplastic 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Prostatic Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1 Multiple Endocrine Neoplasia Type 2b 1 Multiple Endocrine Neoplasia Type 2a 1 Multiple Endocrine Neoplasia 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Esthesioneuroblastoma, Olfactory 1 Differentiated Thyroid Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms, Male 1 Breast Neoplasms 1

Interventions

3-Iodobenzylguanidine 8 lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 5 Temozolomide 4 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 anlotinib 3 Everolimus 3 olaparib 2 cabozantinib 2 belzutifan 2 Sunitinib 2 Phenoxybenzamine 2 Nivolumab 2 Fluorodeoxyglucose F18 2 Biopsy 2 Axitinib 2 3-fluorobenzylguanidine 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 vandetanib 1 talazoparib 1 spartalizumab 1 pembrolizumab 1 pazopanib 1 lanreotide 1 guadecitabine 1 fluorodopa F 18 1 fludarabine phosphate 1 copper dotatate CU-64 1 cixutumumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡